Imeik Technology Development Co

Imeik Technology Development Co Debt/EBITDA

The Total Debt to EBITDA Ratio of Imeik Technology Development Co (300896.SZ) as of Oct 17, 2026 is 0.02. In the previous year, Total Debt to EBITDA Ratio was 0.02 — a change of -19.19% (lower).

Debt/EBITDA

0.02

YoY

-19.19%

Last updated:

Total Debt to EBITDA Ratio of Imeik Technology Development Co is 2024 0.02 . Total Debt to EBITDA Ratio of Imeik Technology Development Co was 2023 0.02 . It decreases by -19.19% lower compared to the previous year.

The Imeik Technology Development Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
0.06 CNY
Jan 1, 2018
0.00 CNY
Jan 1, 2019
0.00 CNY
Jan 1, 2020
0.00 CNY
Jan 1, 2021
0.04 CNY
Jan 1, 2022
0.04 CNY
Jan 1, 2023
0.02 CNY
Jan 1, 2024
0.02 CNY
The Imeik Technology Development Co Debt/EBITDA history
YEARDebt/EBITDAYoY
0.02-19.19%
0.02-39.68%
0.04-6.26%
0.04—
0.00—
0.00—
0.00-100.00%
0.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Imeik Technology Development Co Stock analysis

What does Imeik Technology Development Co do? Imeik Technology Development Co Ltd is a biotechnology company based in Beijing, China, operating within the healthcare sector. The company focuses on the research, development, and industrialization of biomedical materials, particularly recombinant proteins and peptides. It has established a product technology transformation platform for biomedical materials, including medical chitosan and polylactic acid. Imeik has successfully industrialized injection-type sodium hyaluronate series products and polydioxanone facial implants. Its self-developed products are primarily designed for the repair of facial and neck skin folds, with clinical applications spanning medical cosmetology, surgical repair, and the treatment of metabolic diseases. The company went public on the Shenzhen Stock Exchange on September 28, 2020, with ticker 300896.SZ and ISIN CNE100004868. Imeik currently employs 713 full-time staff and operates exclusively within the Chinese market. Its website is www.imeik.net, providing information on its products and services. The company emphasizes the development and transformation of biomedical materials, aiming to advance biomedicine through its specialized focus on recombinant proteins and peptides. It has developed a range of products that address specific medical and cosmetic needs, contributing to its position in the healthcare industry. Imeik Technology Development Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imeik Technology Development Co stock

Total Debt to EBITDA Ratio of Imeik Technology Development Co is 0.02 in 2024.

Total Debt to EBITDA Ratio of Imeik Technology Development Co changed from 0.02 to 0.02, representing a -19.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Imeik Technology Development Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Imeik Technology Development Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Imeik Technology Development Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Imeik Technology Development Co